7 results
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
1 Jun 23
Catalyst Pharmaceuticals Reports Positive Momentum in Reaffirms Full Year 2023 Total Revenue Guidance of Between
4:30pm
sustainable growth and deliver value for our shareholders.”
Financial Guidance for Full Year 2023
The Company’s 2023 financial guidance reflects
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
10 May 22
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
4:31pm
that we believe position us to deliver sustainable long-term growth for FIRDAPSE. We anticipate this to be a transformative year for Catalyst, as we
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
16 Mar 22
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:53pm
of driving long-term sustainable growth.
Partnered with rare disease patients and advocacy groups supporting the 2022 Global Rare Disease Day
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
7 Feb 22
2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth
4:49pm
will further empower us to execute on our strategic objectives to build a differentiated portfolio of products to drive long-term sustainable growth … to treat rare diseases which are currently without any approved therapy to drive long-term sustainable growth.
About Catalyst Pharmaceuticals
Catalyst
8-K
EX-99.1
1bihi6cewq
9 Nov 21
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:29pm
8-K
EX-99.1
19viroqd
17 Dec 18
Commercial Launch of Firdapse
12:00am
- Prev
- 1
- Next